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Although current therapies have improved leukemia survival rates, adverse drug effects 
and relapse are frequent. Encapsulation of edelfosine (ET) in lipid nanoparticles (LN) 
improves its oral bioavailability and decreases its toxicity. Here we evaluated the 
efficacy of ET-LN in myeloid leukemia cell lines. Drug-loaded LN were as effective as 
free ET in sensitive leukemia cell lines. Moreover, the encapsulated drug overcame the 
resistance of the K562 cell line to the drug. LN containing ET might be used as a 
promising drug delivery system in leukemia due to their capacity to overcome the in 
vivo pitfalls of the free drug and their efficacy in vitro in leukemia cell lines. 
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 Table 1 
Physicochemical characteristics of the developed LN (mean ± SD) 







Blank-LN 123.80 ± 9.02  0.260 ± 0.015  ‐28.1 ± 2.4  ‐‐  ‐‐ 
Drug-loaded LN 104.83 ± 3.40  0.248 ± 0.006  ‐26.5 ± 5.6  75.75 ± 10.26  13.02 ± 0.99 
NR-LN 117.53 ± 1.58  0.246 ± 0.010  ‐21.5 ± 0.4  ‐‐  ‐‐ 
Drug-loaded NR-LN 103.27 ± 1.65  0.260 ± 0.010  ‐14.9 ± 0.5  91.86 ± 9.11  11.87 ± 1.52 
 
Table 2.  
IC50 values of leukemia cell lines alter 72 h of incubation with free-ET and Drug-loaded LN. 
Cell type Cell name Free-ET (µM) Loaded LN (µM) 
Human acute myeloid leukemia HL-60 3.48 8.64 
Human acute myeloid leukemia OCI-AML-2 0.64 0.22 
Human acute myeloid leukemia MOLM-13 3.64 3.41 
Human erythroleukemia HEL 4.42 7.96 





Figure 1. TEM images of blank-LN (a) and Drug-loaded LN (b). 
  
 
Figure 2. Dose- reponse curve in sensitive (MOLM-13) and resistant (K-562) cells at 72 hours of 
incubation with different doses of free ET or drug-loaded LN.  
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Figure 3. Apoptosis induced in OCI-AML-2 (sensitive cells) by the different treatments (9.5 µM of 
ET) after 24 h and 72 h of incubation. **p<0.01; ***p<0.001 vs. control by two-way ANOVA 
(Bonferroni post-test). 
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Figure 4. Apoptosis induced in sensitive cell lines by the different treatments (19 µM of ET) after 72 
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Figure 5. Flow cytometry graphs of apoptosis induced in HL-60 and K562 cells after 72 hours of 
incubation with medium, blank-LN, free ET and drug-loaded LN at a dose equivalent to 19 µM 
(HL-60) and 28.6 µM (K562) of free ET.  *p<0.05; **p<0.01; ***p<0.001 vs. control by two-way 
ANOVA (Bonferroni post-test).  
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Figure 6. (A) Free and nanoencapsulated drug effect in cell cycle distribution in sensitive (HEL) 
and resistant (K562) cells after 24 (A) and 72 (B) hours of incubation. Cells were treated with 
medium, blank-LN, free ET and drug-loaded LN at a dose equivalent to 9.5 µM of ET (HEL) and 
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Figure 7. Analysis of cell cycle distribution in sensitive cell lines by the different treatments (at a 
dose corresponding to 19 µM of ET) after 72 h of incubation. *p<0.05; **p<0.01; ***p<0.001 vs. 
control by two-way ANOVA (Bonferroni post-test).  
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Figure 8. (A) Fluorescence images of HL-60 cells cultured with NR-LN for different incubation 
times. (B) Flow cytometry graph corresponding to NR-LN uptake by HL-60 cells after 3 hours of 
incubation with NR-LN. (C) Flow cytometry analysis of NR-LN uptake within the time (3 hours) 
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Figure 9. (A) Fluorescence images of K562 cells cultured with NR-LN for different incubation 




















































































Figure 10. Caspase-9, 8 and 3 activation in HL-60 (sensitive) and K562 (resistant) cells by flow 
cytometry. Cells were untreated (control), treated with free ET (Free-ET) or drug-loaded LN 
(Loaded-LN) with a dose equivalent to 19 µM free ET and analyzed after 72 hours of incubation. 
 
 
